Able Labs Recall Of All Marketed Products Boosts 2005 Drug Recall Total
Generic drug manufacturer Able Laboratories' recall of all of its marketed products following an FDA GMP inspection accounted for half of the substantial rise of products recalled during 2005 versus the previous year
You may also be interested in...
Able Labs routinely failed to reject drugs that did not meet established standards, specifications and quality control criteria, according to FDA inspectional observations included in a "Form 483" report
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials